United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for United Therapeutics in a research note issued on Thursday. Leerink Swann analyst J. Schwartz expects that the biotechnology company will post earnings of $3.38 per share for the quarter. Leerink Swann also issued estimates for United Therapeutics’ Q2 2018 earnings at $3.42 EPS and FY2018 earnings at $10.66 EPS.
Other equities analysts have also issued reports about the company. TheStreet upgraded United Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, December 15th. ValuEngine lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 target price for the company in a research note on Monday, January 15th. BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Oppenheimer upped their target price on United Therapeutics to $180.00 and gave the company an “outperform” rating in a research note on Friday, January 5th. Five equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. United Therapeutics has a consensus rating of “Hold” and an average target price of $135.20.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.59 by $0.30. The firm had revenue of $464.70 million during the quarter, compared to analyst estimates of $420.55 million. United Therapeutics had a return on equity of 24.41% and a net margin of 24.22%. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.12 earnings per share.
In other United Therapeutics news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $134.72, for a total transaction of $78,137.60. Following the completion of the sale, the director now owns 1,555 shares of the company’s stock, valued at $209,489.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,241 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $128.95, for a total value of $160,026.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,822 shares of company stock valued at $238,301. 7.80% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the business. Xact Kapitalforvaltning AB boosted its position in shares of United Therapeutics by 3.8% in the fourth quarter. Xact Kapitalforvaltning AB now owns 11,474 shares of the biotechnology company’s stock worth $1,698,000 after buying an additional 424 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in shares of United Therapeutics by 99.4% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 5,967 shares of the biotechnology company’s stock worth $883,000 after buying an additional 2,974 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in shares of United Therapeutics in the fourth quarter worth about $902,000. MetLife Investment Advisors LLC purchased a new stake in shares of United Therapeutics in the fourth quarter worth about $4,045,000. Finally, Macquarie Group Ltd. boosted its position in shares of United Therapeutics by 33.9% in the fourth quarter. Macquarie Group Ltd. now owns 17,000 shares of the biotechnology company’s stock worth $2,499,000 after buying an additional 4,300 shares during the period.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.